Objectives: Although several reports suggest an increased thromboembolic event rate, especially regarding strokes and TIAs at early age in patients with Fabry disease (FD), the risk for patients with FD to experience these events, the clinical relevance of additional risk factors including the concurrence of factor V Leiden (FVL), and the benefit of enzyme replacement therapy (ERT) regarding these events remain unclear.
Fabry disease (FD; OMIM #301500) is an X-linked (Xq22.1) inborn error of glycosphingolipid catabolism resulting from deficient a-galactosidase A (GLA) (*300644) activity. Fabry-specific manifestations, such as early stroke, malignant arrhythmia, myocardial infarction, as well as progressive renal and cardiac failure, result from the differential systemic cellular accumulation of globotriaosylceramide (Gb3). 1 FD manifestations and early death may be partly avoided or delayed by early enzyme replacement therapy (ERT). 1, 2 Vasculopathy has a compelling pathophysiologic impact on FD manifestations. Proposed mechanisms are abnormal blood flow and vessel architecture, endothelial dysfunction, and prothrombotic state. 3, 4 Several studies substantiated a high and early incidence of stroke and TIAs in patients with FD. [5] [6] [7] [8] This clinical peculiarity may be complicated by the concurrence of other prothrombotic risk factors such as factor V Leiden (FVL; c.1691G.A [R506Q]). FVL heterozygosity increases the risk of thromboembolic events such as deep vein thrombosis (DVT) compared with noncarriers. 9 Even if the FVL mutation as such does only slightly increase the risk of stroke in the general population, 10, 11 the concurrence of FD and FVL has been suggested to translate into increased ischemic cerebral lesions and a potentially higher stroke risk. [12] [13] [14] In the current report, we investigated the risk of thromboembolic events with and without the concurrence of FVL in a large cohort of well-characterized, consecutively recruited patients with FD from 2 main German Fabry centers and analyzed the clinical impact of ERT in a retrospective study design.
METHODS Standard protocol approvals, registrations, and patient consents. All investigations were performed after approval of the Medical Association of Westfalian-Lippe and the ethical committees of the medical faculties of the University of Muenster (project 2011-347-f, date of report July 7, 2011) and the Johannes Gutenberg University of Mainz (project 010-308, date of report April 25, 2012) . Written informed consent was obtained from all patients.
Study design and patients. Between 2000 and 2012, 304 patients with genetically confirmed FD were consecutively recruited at Fabry centers in Muenster and Mainz (Muenster, n 5 123; Mainz, n 5 181). The patient data were analyzed from the time of their recruitment to the study base.
Genotyping for GLA gene mutations was performed by direct sequencing of all 7 coding exons including adjacent intron-exons boundaries as reported previously. 15 A detailed overview of detected GLA mutations (n 5 96) and appropriate phenotype is provided in table e-1 on the Neurology ® Web site at Neurology.org.
Genotyping for the FVL mutation (c.1691G.A [R506Q]) was performed by amplification and direct sequencing of a 267-base pair fragment in the DNA of 226 patients with FD (Muenster, n 5 123; Mainz, n 5 103) using the oligonucleotide combination FVL_sense (59-TGCCCAGTGCTTAACAAG-39) and FVL_antisense (59-TGTTATCACACTGGTGCTAA-39). Subsequent sequencing of both DNA strands was performed. Seventy-eight patients with FD from Mainz were not genotyped for the FVL mutation because of unavailable DNA samples.
Diagnostic criteria for thromboembolic events and variables. According to clinical routine procedures, thromboembolic events were defined as stroke, TIA, DVT, and pulmonary embolism (PE). Stroke/TIA patients were classified according to Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. 16 The classification is based on documented data including clinical history with the assessment of main risk factors (hypertension, hyperlipidemia, diabetes mellitus, family history of vascular disease), blood tests including thrombophilic risk factors, Holter ECG, assessment of extracranial arteries (carotid ultrasound examination, or angiography), and cerebral CT/MRI according to Amarenco et al. 16 Events that were not classifiable according to TOAST criteria were excluded from subsequent analyses. Risk factors and confounders for thromboembolic events included essential hypertension (defined as systolic blood pressure $140 mm Hg, diastolic blood pressure $90 mm Hg, or the use of antihypertensive drugs; secondary forms of hypertension were excluded where appropriate by standard laboratory and imaging techniques), type 2 diabetes mellitus (defined as fasting plasma glucose $7.0 mmol/L [$126 mg/dL] or the use of antidiabetic drugs), hypercholesterolemia (defined as cholesterol level $200 mg/dL, or use of lipid-lowering drugs), smoking, body mass index (BMI), sex, and age. Blood pressure was measured with auscultatory sphygmomanometers at the upper arm with cuff and bladder dimensions adapted to the arm circumference in a quiet room after 5 minutes of rest, with the patient in a seated position, back and arm supported according to current European Society of Hypertension/European Society of Cardiology Guidelines. 17 Duration of ERT (agalsidase-alfa or agalsidase-beta) was assessed as the time difference from start of ERT until the occurrence of a thromboembolic event or to the last visit (event-free censoring).
Statistical analysis. Three hundred four subjects from the 2 Fabry centers were included in the analysis for thromboembolic events. If not otherwise stated, continuous variables were expressed as median (range) and categorical data as numbers and relative frequencies. Differences between groups were analyzed with the Student t or Mann-Whitney U test for continuous data, and the Fisher exact test for categorical data. Statistical significance was considered at a 2-sided p , 0.05. Event rates were calculated per 100 person-years of observation as described above. Cox proportional hazard models were used to determine the influence of FVL on the hazard rate for thromboembolic events and adapted according to Krall et al. 18 We adjusted for confounders such as age, sex, BMI, hypertension, type 2 diabetes mellitus, hypercholesterolemia, and smoking. The significance for additional thromboembolic events was calculated using the Fisher exact test. Furthermore, we applied stepwise Cox regression analyses with forward selection (level for entry: 0.10; level for stay: 0.10) to determine the influence of initiation of ERT on the risk of thromboembolic event rates according to Crowley and Hu. 19 All results are reported with their respective 95% confidence intervals (CIs). SAS version 9.3 (SAS Institute Inc., Cary, NC) was used for all statistical analyses.
RESULTS
Of the 304 patients with FD from 2 German Fabry centers, 123 patients were recruited at the Fabry center in Muenster and 181 at the Fabry center in Mainz between January 2000 and December 2012. Our analysis involved total lifetime events of patients with FD including stroke, TIA, DVT, and PE until the event or the beginning of ERT treatment to exclude the effect of ERT. Table 1 demonstrates that the majority of the patient cohort was female and their average age was 41 years. We identified 96 different GLA mutations in the 304 patients. Mutations and respective clinical phenotypes are presented in table e-1. About 2 of 3 patients received ERT at the time point of data analysis. Among all patients with FD, 14.1% had experienced at least one stroke or TIA, while 3.3% experienced a DVT or PE. Sixty-seven percent of all neurologic events were of "undetermined origin" because of undetermined origin (46%) or several concurrent reasons (21%, mostly microangiopathic with a concurrent cardioembolic origin). Fourteen percent were of "microangiopathic origin." Five percent were of "cardioembolic origin" due to atrial fibrillation or patent foramen ovale. Furthermore, 7% were classified as "other determined origin," due to homozygous FVL mutations or protein S deficiency. No patient was detected with vasculitis or vascular dissection, or clinically relevant carotis stenosis as possible origin of stroke. Seven percent of the events could not be classified according to TOAST criteria because of single missing examination for correct classification (for example, missing Holter ECG to exclude atrial fibrillation, etc.). The classification according to TOAST represents a rather typical etiology of ischemic cerebral events in patients with FD. [20] [21] [22] [23] A total of 53 patients (17.4%) were identified with at least one thromboembolic event during their lifetime (figure). Considering multiple thromboembolic events, a total of 89 lifetime occurrences were reported with an average of 1.68 events per affected patient with FD.
There were 226 patients with FD (Muenster, n 5 123; Mainz, n 5 103) with a known status for the FVL mutation (R506Q) (table 2, figure). Thirteen patients with FD were heterozygous and 3 homozygous for the FVL mutation, distributed in 12 unrelated families. For further analysis, the hetero-and homozygous FVL patients were combined (n 5 16, table 2). The detected frequency of 7.1% for FVL was in line with the distribution in general Caucasian populations. 9 Age, sex, and ERT as well as the classic risk factors for thromboembolic events, such as BMI, hypertension, hypercholesterolemia, type 2 diabetes mellitus, and smoking, revealed no significant differences between FD patients with and without the concurrence of FVL (table 2) . ERT duration differed moderately, in that patients with FVL had shorter treatment durations than those without FVL (p 5 0.0438 , table 2 ).
To analyze the putative effect of FVL on thromboembolic risk in patients with FD in detail, we evaluated only the occurrence of thromboembolic events before ERT was started in a patient, retrospectively. Therefore, the time under risk covered the period from a patient's birth until event occurrence, start of ERT, or end of the observation (censoring). Among 226 patients with FD, 13.7% experienced thromboembolic events, mainly strokes or TIAs (10.2%) (table 3, figure ). The risk of thromboembolic events (including stroke, TIA, DVT, and PE) in patients with FD and concurrent FVL was clearly increased. This risk for FVL carriers remained high after correction for confounders in a Cox regression analysis (table 3, figure) and the hazard ratio (HR) was 5.45 (p , 0.001; table 3, figure) . The adjusted HRs also remained significant in separate analyses for stroke/TIA (p 5 0.0272) and DVT/PE (p 5 0.0018; table 3).
In addition, we analyzed the frequency and the risk of cumulative thromboembolic events in FD patients with and without FVL. During the observation period, 23 patients with FD presented 37 events (17 patients with one event and 6 patients with more than one event), and 8 patients with FD and concurrent FVL presented 21 events (3 patients with one event and 5 patients with more than one event). These results indicated a trend toward an increased risk of additional thromboembolic events in patients with FD and concurrent FVL (relative risk 5 1.558, 95% CI 0.880-2.756; p 5 0.0947).
ERT and the risk of thromboembolic events in patients with FD. To analyze the effect of ERT on the risk of thromboembolic events in patients with FD, we performed an additional Cox regression analysis using the ERT status between 2000 (first commercial availability of ERT) and 2012 (end of the study). Inclusion criteria were no thromboembolic events before 2000 and at least one further visit after first assessment at the Fabry centers. Because of the detected effect of FVL on the risk of thromboembolic events, FVL carriers and patients with unknown FVL status were excluded from this part of the analysis. The time under risk for each patient with FD was calculated as the time until a first thromboembolic event occurred or the last visit in 1 of the 2 Fabry centers. By using this model, the following situations may occur: (1) patients under risk of a thromboembolic event are not receiving ERT; or (2) patients under risk of a thromboembolic event are receiving ERT. Therefore, patients were all the time not receiving ERT, patients were all the time receiving ERT, or patients were first not receiving ERT and then started with ERT. Of note, once ERT started, it was given continuously and none of the patients stopped infusions.
In a first step, the effect of ERT on thromboembolic events was analyzed in a descriptive analysis of Table 1 Baseline clinical characteristics and parameters of the study population Stroke and TIA are common and serious clinical manifestations in FD, 5 with an overall prevalence of 13%, 8 and a high risk of additional events. 6, 20 In our cohort of 304 patients with FD, we identified a comparable prevalence of approximately 14%. Several case studies exist, indicating that the concurrence of FD and FVL may lead to an increased formation of ischemic cerebral lesions and increased risk of stroke. [12] [13] [14] 24 In addition, double knockout mice with a deficiency for GLA and FVL showed increased tissue fibrin deposition and thrombosis in different tissues, underlining a synergistic effect of both inborn errors in Fabry vasculopathy. 25 After correction for classic risk factors for cerebrovascular as well as thrombotic events, such as sex, smoking, BMI, hypercholesterolemia, hypertension, and type 2 diabetes mellitus, in our study, the risk of thromboembolic events in patients with FD and concurrent FVL was increased 5.45-fold compared to those without FVL. Of note, Heit et al. 26 reported that the risk of venous thromboembolic events (DVT or PE) in heterozygous FVL carriers (patients without FD) increased 3.6-fold for patients older than 60 years, highlighting age as an important risk factor in patients with FVL. In our study, patients with FD and concurrent FVL had an earlier decrease of eventfree survival, starting at the average age of 30 years (data not shown). This suggests that the deleterious and age-dependent effect of FVL 26 may be observed at an even earlier age in FD. In the current study, when considering FVL carriers with stroke/TIA or DVT/PE separately, the analysis showed an approximately 3.4-fold increase for stroke/TIA and an approximately 14.8-fold increase for DVT/PE. Consequently, our results confirm former case reports [12] [13] [14] and general clinical observations in FD centers (C. Kurschat, Fabry Center Cologne, and F. Weidemann, Fabry Center Wuerzburg, personal communication, 2014), in that the risk of stroke/TIA in patients with FD and concurrent FVL is significantly increased.
During the entire observation period, the relative risk for cumulative events was approximately 1.6-fold higher in FVL carriers. This indicates a clinically Table 2 Clinical characteristics of the study population without (2) relevant increased risk of additional thromboembolic events in patients with FD and FVL and the need of close clinical monitoring.
Since an increased risk of thromboembolic events in general results in increased morbidity and mortality, we strongly recommend that in patients with these events, an additional diagnostic screening for thrombophilic risk markers such as the FVL mutation as well as FD is warranted. In the case of a concurrence of FD and an additional thrombophilic risk factor, such as the FVL mutation, we strongly recommend counseling the patient in avoiding additional risk factors for venous thromboembolism (e.g., use of combined oral contraceptives, hormone replacement therapy) and providing pharmacologic anticoagulant prophylaxis in thrombophilic risk situations (surgery, immobilization, long-distance flights, postpartum period, etc.). In addition, strict blood pressure and lipid monitoring and the use of reninangiotensin-aldosterone system inhibitors or statins where appropriate should be performed to prevent progression of vasculopathy. According to current general guidelines for stroke prevention, acetylsalicylic acid treatment should only be considered for primary stroke prevention for persons whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment (a 10-year risk of cardiovascular events of 6%-10%). 27 However, regarding our results and in accordance with the current Fabry expert opinions and German FD guidelines, 5,28,29 primary prevention of thromboembolic events including antiplatelet therapy should be considered in patients with FD especially with a concurrence of FVL.
The benefit of ERT has already been shown for different Fabry-related symptoms and organ manifestations. ERT reduces neuropathic pain and gastrointestinal symptoms, leads to a stabilization of renal and cardiac function and structural involvement, reduces the frequency of clinically significant renal and cardiovascular events, and prolongs life expectancy. 1, 2, 30, 31 Several studies have shown the optimal benefit when ERT is started at an early disease stage before extensive fibrosis or other irreversible tissue damage occurs. [32] [33] [34] [35] In our retrospective study, we demonstrate that patients with FD not receiving ERT had an approximately 2.8-fold higher risk of thromboembolic events compared with patients receiving ERT. However, the moderate p value associated with this risk makes the result sensitive to a small change in the events per analyzed group. Regarding the arterial and venous system, we could show that the risk of stroke and TIA as well as of DVT and PE in patients with FD not receiving ERT was increased. According to our observations, ERT might be of benefit in preventing vascular events.
The retrospective design of our study is a limitation since no conclusions should be drawn concerning the exact risk of future thromboembolic events once FD is diagnosed in the concurrence of FVL. Therefore, prospective and controlled clinical studies are warranted to quantify the increased risk of future thromboembolic events in patients with FD in a concurrence of FVL after diagnosis and the risk reduction of thromboembolic events by ERT.
In conclusion, patients with FD have a high risk of clinically relevant thromboembolic events, which might be prevented by ERT. In our retrospective study, the concurrence of FD and FVL led to an even higher risk of thromboembolic events. Future prospective studies are needed to clarify which patients with the combination of FD and other thrombophilic risk factors benefit from more intensive oral anticoagulant strategies. 
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